Tozinameran: Myocarditis.

A 37-year-old woman developed myocarditis after receiving the tozinameran COVID-19 vaccine. She had no previous cardiovascular disease but experienced symptoms such as fatigue, dyspnea, and peripheral edema. Tests showed left ventricular enlargement and dysfunction. The woman was treated with various medications and underwent MRI, which revealed improvement in her condition over a six-month follow-up period. [Extracted from the article]